

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7196672

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	STEVEN RICH	02/22/2021
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	QAAM PHARMACEUTICALS, LLC	
<b>Street Address:</b>	4884 NORTH ROAD	
<b>City:</b>	CANANDAIGUA	
<b>State/Country:</b>	NEW YORK	
<b>Postal Code:</b>	14424	
<b>PROPERTY NUMBERS Total: 1</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	17163010	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	6072562000	
<b>Email:</b>	docket@bpmlegal.com	
<b>Correspondent Name:</b>	BROWN & MICHAELS, PC	
<b>Address Line 1:</b>	118 N TIOGA ST	
<b>Address Line 2:</b>	4TH FLOOR	
<b>Address Line 4:</b>	ITHACA, NEW YORK 14850	
<b>ATTORNEY DOCKET NUMBER:</b>	RI1-9004	
<b>NAME OF SUBMITTER:</b>	GARTH E. COVIELLO	
<b>SIGNATURE:</b>	/Garth E. Coviello/	
<b>DATE SIGNED:</b>	02/26/2022	
<b>Total Attachments: 2</b>		
source=RI1-9004 Dec_Assign#page1.tif		
source=RI1-9004 Dec_Assign#page2.tif		

**COMBINED ASSIGNMENT AND DECLARATION**

For value received, I, Steven A. Rich, MD, of Canandaigua in the State of New York, hereby sell, assign, and transfer to QAAM Pharmaceuticals, LLC, having an office at 4884 North Road, Canandaigua, New York, 14424, and its successors, assigns, and legal representatives (hereinafter referred to as the "Assignee"), the entire right, title, and interest, for the United States of America, in and to certain inventions related to the FIXED DOSE COMBINATION OF CHOLINESTERASE INHIBITOR AND A QUATERNARY AMMONIUM ANTIMUSCARINIC AGENT TO TREAT NEURODEGENERATIVE COGNITIVE DISORDERS described in an application for Letters Patent of the United States, executed by me, and all the rights and privileges in said application and under any and all Letters Patent that may be granted in the United States for said inventions.

I also concurrently hereby sell, assign, and transfer to Assignee the entire right, title, and interest in and to said inventions for all countries foreign to the United States, including all rights of priority arising from the application aforesaid, and all the rights and privileges under any and all forms of protection, including Letters Patent, that may be granted in said countries foreign to the United States for said inventions.

I authorize Assignee to make application for such protection in its own name and maintain such protection, and to invoke and claim for any application for patent or other form of protection for said inventions, without further authorization from me, any and all benefits, including the right of priority provided by any and all treaties, conventions, or agreements. I request that any and all patents for said inventions be issued to Assignee, or to such nominees as Assignee may designate.

I hereby consent that a copy of this assignment shall be deemed a full legal and formal equivalent of any document which may be required in any country in proof of the right of Assignee to apply for patent or other form of protection for said inventions and to claim the aforesaid benefit of the right of priority.

I agree that, when requested, I shall, without charge to Assignee, but at its expense, sign all papers, and do all acts which may be necessary, desirable or convenient in connection with said applications, patents, or other forms of protection.


I hereby declare that:

- My residence and mailing address are as stated below next to my name.
- The above-identified application was made or authorized to be made by me.
- I believe that I am an original inventor or joint inventor of the subject matter which is claimed in the above-identified application.
- I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.
- I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available

between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

- I hereby acknowledge that any willful false statement made in this declaration is punishable under Section 1001 of Title 18 of the United States Code by fine or imprisonment of not more than five (5) years, or both.

Inventor:

Handwritten signature of Steven A. Rich, MD, in black ink on a white background.

02/22/2021


Date

Name: Steven A. Rich, MD

Residence: US

Mailing Address: 4884 North Road  
Canandaigua, NY 14424

Assignee:

Handwritten signature of Steven A. Rich, MD, in black ink on a white background.

By: \_\_\_\_\_

02/22/2021

Date

Name: Steven A. Rich, MD

Title: Chief Executive Officer, QAAM Pharmaceuticals, LLC